LabCorp takes Qiagen nucleic acid robot:
This article was originally published in Clinica
LabCorp is to use Qiagen's BioRobot 9604 and QIAamp 96 viral ribonucleic acid (RNA) kit as a standard package for high-throughput nucleic acid sample preparation. LabCorp will use the two products in its HIV resistance testing services. Qiagen, a Valencia, California-based subsidiary of the Dutch holding company Qiagen NV, says the combination automates the manual process of viral RNA purification. LabCorp carries out diagnostic tests for physicians, hospitals and clinics.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.